Zenas Posts $647M Cash, EMA Validates Obexelimab MAA Ahead of May 2027 PDUFA
ZBIO has more than doubled off its 52-week low of $13.5.
Summary
Zenas ended Q3 with $647.1 million in cash, cash equivalents and investments, down from $673.9 million at mid-year as R&D and pre-commercial spending ramped. The EMA validated the obexelimab MAA for IgG4-RD, adding a second regulatory track alongside the FDA BLA accepted in August with a PDUFA date of May 27, 2027. Revenue was $10.0 million from a Bristol Myers Squibb development milestone, but the net loss widened to $108.9 million ($1.65 per share) from $51.5 million a year ago on higher R&D ($58.5M), G&A ($27.4M) and $27.5 million of acquired IPR&D tied to InnoCare and Xencor milestones. Management says cash funds operations at least through Q2 2029, assuming a $75 million Royalty Pharma milestone and $75 million drawn from the Pharmakon debt facility on FDA approval. Two near-term readouts matter most: Phase 2 SunStone topline in SLE and initial Phase 1 ZB021 data, both expected in Q4 2026.
At the time of this announcement, ZBIO was trading at $28.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $13.50 to $44.60. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.